

SPECIALTY QUANTITY LIMIT PROGRAM

COMETRIQ (cabozantinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of medullary thyroid cancer, follicular, Hurthle, and papillary thyroid cancer, and non-small cell lung cancer with RET gene arrangements fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Cometriq (cabozantinib) Kit 60 mg daily dose blister cards Kit	1 Kit (84 capsules of 20 mg) per 28 days	140 mg orally once daily
Cometriq (cabozantinib) Kit 100 mg daily dose blister cards Kit	1 Kit (28 capsules of 20mg, 28 capsules of 80 mg) per 28 days	140 mg orally once daily
Cometriq Kit (cabozantinib) 140 mg daily dose blister cards Kit	1 Kit (84 capsules of 20 mg, 28 capsules of 80 mg) per 28 days	140 mg orally once daily

III. REFERENCES

1. Cometriq [package insert]. South San Francisco, CA: Exelixis; October 2017.